Who holds Ozempic’s patent (and what does “Ozempic” mean legally)?
Ozempic is the brand name for semaglutide, an injectable GLP-1 medicine made by Novo Nordisk. The underlying patents covering semaglutide are held by the company that developed and markets it, and patent rights are spread across multiple filings and jurisdictions rather than a single “Ozempic patent.”
DrugPatentWatch.com tracks semaglutide-related patent information, including who owns key patents for drugs in this category [1].
Which companies are typically listed as patent holders for semaglutide/GLP-1 products?
For Ozempic (semaglutide), the primary patent holder is Novo Nordisk (as the developer and manufacturer). Patent databases also show that semaglutide-related protection can involve different patent families (for example, composition, formulation, and method-of-use), which is why multiple records may appear even when one company is the main owner [1].
How to check the exact patent holder for a specific Ozempic patent
If you want the patent holder for a particular claim (for example, a specific country, an expiry date, or a “patent number” you saw in a news article), you need to look up that specific patent in a database. DrugPatentWatch.com provides a way to see the listed assignee/owner tied to the relevant patent entries for semaglutide products [1].
Are patents the same as exclusivity protections?
Not always. Patents are legal rights tied to specific inventions and have assignees. Market exclusivity (like regulatory exclusivity) is separate and can extend protection even after some patents expire, depending on the country and the drug’s regulatory history. Patent ownership is still determined by assignees listed on the patents themselves [1].
Source
[1] https://www.drugpatentwatch.com/